Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation

PHASE2CompletedINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Primary Liver Cancer
Interventions
DEVICE

Transarterialchemoembolisation (TACE)

DEVICE

DC Bead with Doxorubicin

Trial Locations (17)

1011

Centre Hospitalier Universitaire Vaudois, Lausanne

1090

Allgemines Krankenhaus Vienna, Vienna

3010

Inselspital Bern, Bern

Hopitaux Universitaires de Geneve, Geneva

6020

Medizinische Universitat Innsbruck, Innsbruck

6200

Hopital Archet II, Nice

8091

Universitatsspital Zurich, Zurich

30625

Medicinische Hochschule Hannover, Hanover

31059

CHU Rangueil, Toulouse

55131

Klinikum der Johannes Guttenberg, Mainz

59037

Hopital Claude Huriez, Lille

60590

Klinikum der Johann-Wolfgang-Goethe-Universitat, Frankfurt am Main

68167

Fakultat fur Klinische Medizin Mannheim Universitat, Mannheim

69437

Groupement Hospitalier Edouard Herriot, Lyon

75013

Hopital Pitie Salpetriere, Paris

92100

L'Hopital Beaujon, Clichy

94805

Institut Gustave Roussy, Villejuif

Sponsors
All Listed Sponsors
collaborator

Biocompatibles UK Ltd

INDUSTRY

lead

Boston Scientific Corporation

INDUSTRY